215 related articles for article (PubMed ID: 27194215)
1. Bioactivity of 2'-deoxyinosine-incorporated aptamer AS1411.
Fan X; Sun L; Wu Y; Zhang L; Yang Z
Sci Rep; 2016 May; 6():25799. PubMed ID: 27194215
[TBL] [Abstract][Full Text] [Related]
2. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
[TBL] [Abstract][Full Text] [Related]
3. AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin.
Cheng Y; Zhao G; Zhang S; Nigim F; Zhou G; Yu Z; Song Y; Chen Y; Li Y
PLoS One; 2016; 11(12):e0167094. PubMed ID: 27907160
[TBL] [Abstract][Full Text] [Related]
4. Toward G-Quadruplex-Based Anticancer Agents: Biophysical and Biological Studies of Novel AS1411 Derivatives.
Ogloblina AM; Iaccarino N; Capasso D; Di Gaetano S; Garzarella EU; Dolinnaya NG; Yakubovskaya MG; Pagano B; Amato J; Randazzo A
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096752
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.
Reyes-Reyes EM; Šalipur FR; Shams M; Forsthoefel MK; Bates PJ
Mol Oncol; 2015 Aug; 9(7):1392-405. PubMed ID: 25911416
[TBL] [Abstract][Full Text] [Related]
6. Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.
Noaparast Z; Hosseinimehr SJ; Piramoon M; Abedi SM
J Drug Target; 2015; 23(6):497-505. PubMed ID: 25673264
[TBL] [Abstract][Full Text] [Related]
7. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.
Soundararajan S; Wang L; Sridharan V; Chen W; Courtenay-Luck N; Jones D; Spicer EK; Fernandes DJ
Mol Pharmacol; 2009 Nov; 76(5):984-91. PubMed ID: 19657047
[TBL] [Abstract][Full Text] [Related]
8. AS1411 Aptamer/Hyaluronic Acid-Bifunctionalized Microemulsion Co-Loading Shikonin and Docetaxel for Enhanced Antiglioma Therapy.
Wang H; Zhu Z; Zhang G; Lin F; Liu Y; Zhang Y; Feng J; Chen W; Meng Q; Chen L
J Pharm Sci; 2019 Nov; 108(11):3684-3694. PubMed ID: 31465736
[TBL] [Abstract][Full Text] [Related]
9. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
Mosafer J; Mokhtarzadeh A
Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
[TBL] [Abstract][Full Text] [Related]
10. Nucleolin Overexpression Confers Increased Sensitivity to the Anti-Nucleolin Aptamer, AS1411.
Sharma VR; Thomas SD; Miller DM; Rezzoug F
Cancer Invest; 2018; 36(9-10):475-491. PubMed ID: 30396283
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy and cardioprotection of nucleolin-targeted doxorubicin-loaded ultrasound nanobubbles in treating triple-negative breast cancer.
Fang K; Wang L; Huang H; Dong S; Guo Y
Nanotechnology; 2021 Mar; 32(24):. PubMed ID: 33690196
[TBL] [Abstract][Full Text] [Related]
12. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism.
Reyes-Reyes EM; Teng Y; Bates PJ
Cancer Res; 2010 Nov; 70(21):8617-29. PubMed ID: 20861190
[TBL] [Abstract][Full Text] [Related]
13. AS1411 Nucleolin-Specific Binding Aptamers Reduce Pathological Angiogenesis through Inhibition of Nucleolin Phosphorylation.
Iturriaga-Goyon E; Vivanco-Rojas O; Magaña-Guerrero FS; Buentello-Volante B; Castro-Salas I; Aguayo-Flores JE; Gracia-Mora I; Rivera-Huerta M; Sánchez-Bartés F; Garfias Y
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884955
[TBL] [Abstract][Full Text] [Related]
14. Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2'-deoxyuridine more capable of specific binding to targets in cancer cells.
Lee KY; Kang H; Ryu SH; Lee DS; Lee JH; Kim S
J Biomed Biotechnol; 2010; 2010():168306. PubMed ID: 20204158
[TBL] [Abstract][Full Text] [Related]
15. Exploring the conformational behaviour and aggregation properties of lipid-conjugated AS1411 aptamers.
Riccardi C; Musumeci D; Russo Krauss I; Piccolo M; Irace C; Paduano L; Montesarchio D
Int J Biol Macromol; 2018 Oct; 118(Pt B):1384-1399. PubMed ID: 30170359
[TBL] [Abstract][Full Text] [Related]
16. The Bioactivity of D-/L-Isonucleoside- and 2'-Deoxyinosine-Incorporated Aptamer AS1411s Including DNA Replication/MicroRNA Expression.
Fan X; Sun L; Li K; Yang X; Cai B; Zhang Y; Zhu Y; Ma Y; Guan Z; Wu Y; Zhang L; Yang Z
Mol Ther Nucleic Acids; 2017 Dec; 9():218-229. PubMed ID: 29246300
[TBL] [Abstract][Full Text] [Related]
17. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
Soundararajan S; Chen W; Spicer EK; Courtenay-Luck N; Fernandes DJ
Cancer Res; 2008 Apr; 68(7):2358-65. PubMed ID: 18381443
[TBL] [Abstract][Full Text] [Related]
18. Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells.
Carvalho J; Paiva A; Cabral Campello MP; Paulo A; Mergny JL; Salgado GF; Queiroz JA; Cruz C
Sci Rep; 2019 May; 9(1):7945. PubMed ID: 31138870
[TBL] [Abstract][Full Text] [Related]
19. Aptamer-integrated α-Gal liposomes as bispecific agents to trigger immune response for killing tumor cells.
Hong S; Ding P; Luo Y; Gao T; Zhang Y; Pei R
J Biomed Mater Res A; 2019 Jun; 107(6):1176-1183. PubMed ID: 30650243
[TBL] [Abstract][Full Text] [Related]
20. AS1411 binds to nucleolin via its parallel structure and disrupts the exos-miRNA-27a-mediated reciprocal activation loop between glioma and astrocytes.
Sun X; Zhang W; Gou C; Wang X; Wang X; Shao X; Chen X; Chen Z
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167211. PubMed ID: 38701957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
